A randomized, open label, two treatments, two periods, two sequence, single dose, crossover, bioequivalence study of Rosuvastatin 20 mg tablet of Aburaihan Pharm Co., IRAN and Crestor 20 mg tablet of Astra-Zeneca in 24 healthy adult subjects under fasting condition

Aburaihan Pharm Co.0 个研究点目标入组 24 人开始时间: 待定最近更新: 2019年10月7日

适应症

试验速览

暂无简介。

•Aged between 18 - 50 years
•- Body weight between 50 – 100 kg
•- Having good health on the basis of medical history and physical & clinical examination
•- Understand the procedures and give written informed consent

•Subject showed clinically relevant deviations from normal in physical examination.
•Subject had undergone surgery of the gastro-intestinal tract
•Subject had donated a unit of blood or participated in another clinical trial, within the last three months before the first treatment
•Subject had a history of drug or alcohol abuse.
•Subject who smokes more than 10 cigarettes per day.
•Subject had used any prescription medication within 14 days, or any non-prescription medication within 7 days, before the first treatment.
•Subject had a history of allergic to statins

发起方

Aburaihan Pharm Co.